Current Cancer Drug Targets

Editor-in-Chief

Ruiwen Zhang
Center for Drug Discovery
University of Houston
3455 Cullen Blvd.
Houston, TX 77204
(USA)

Personal Subscription
Become EABM
Become Reviewer
Call for Editor
Volume: 10 Issue: 8, December

EDITORIAL [Hot topic: RAS - A Central Feature in Cancer Targeted Therapy (Guest Editor: Balazs Gyorffy)

Volume:10   Issue: 8
Pp: 797-798
Balazs Gyorffy
DOI: 10.2174/156800910793358023
Published on: 01 March, 2012

Predictive Molecular Markers of Response to Epidermal Growth Factor Receptor(EGFR) Family-Targeted Therapies

Volume:10   Issue: 8
Pp: 799-812
Sarah Barton, Naureen Starling and Charles Swanton
DOI: 10.2174/156800910793357925
Published on: 01 March, 2012

KRAS Mutation Testing of Colorectal Cancer for Anti-EGFR Therapy: Dogmas Versus Evidence

Volume:10   Issue: 8
Pp: 813-823
J. Timar, B. Hegedus and E. Raso
DOI: 10.2174/156800910793357989
Published on: 01 March, 2012

Strategies for Overcoming Inherent and Acquired Resistance to EGFR Inhibitors by Targeting Downstream Effectors in the RAS/PI3K Pathway open access plus

Volume:10   Issue: 8
Pp: 824-833
A. J. Weickhardt, N. C. Tebbutt and J. M. Mariadason
DOI: 10.2174/156800910793357961
Published on: 01 March, 2012

RAS Pathways in Prostate Cancer - Mediators of Hormone Resistance?

Volume:10   Issue: 8
Pp: 834-839
H. C. Whitaker and D. E. Neal
DOI: 10.2174/156800910793358005
Published on: 01 March, 2012

Targeting Ras-RAF-ERK and its Interactive Pathways as a Novel Therapy for Malignant Gliomas

Volume:10   Issue: 8
Pp: 840-848
H.-W. Lo
DOI: 10.2174/156800910793357970
Published on: 01 March, 2012

The Crosstalk of RAS with the TGF-β Family During Carcinoma Progression and its Implications for Targeted Cancer Therapy

Volume:10   Issue: 8
Pp: 849-857
M. Grusch, M. Petz, T. Metzner, D. Ozturk, D. Schneller and W. Mikulits
DOI: 10.2174/156800910793357943
Published on: 01 March, 2012

Biomarkers Downstream of RAS: A Search for Robust Transcriptional Targets

Volume:10   Issue: 8
Pp: 858-868
B. Gyorffy and R. Schafer
DOI: 10.2174/156800910793357916
Published on: 01 March, 2012

Ras-Induced Senescence and its Physiological Relevance in Cancer

Volume:10   Issue: 8
Pp: 869-876
T. DiMauro and G. David
DOI: 10.2174/156800910793357998
Published on: 01 March, 2012

EDITORIAL [Hot topic: New Therapeutic Advances and Perspectives in Tumour Angiogenesis (Guest Editor: Eddy Pasquier)]

Volume:10   Issue: 8
Pp: 877-878
Eddy Pasquier and Nicolas Andre
DOI: 10.2174/156800910793358032
Published on: 01 March, 2012

Anti-Angiogenic Therapies for Children with Cancer

Volume:10   Issue: 8
Pp: 879-889
N. Andre, A. Verschuur, J. Rossler and J. Sterba
DOI: 10.2174/156800910793357899
Published on: 01 March, 2012

Implication of Heat Shock Protein 90 (HSP90) in Tumor Angiogenesis: A Molecular Target for Anti-Angiogenic Therapy?

Volume:10   Issue: 8
Pp: 890-897
K. Staufer and O. Stoeltzing
DOI: 10.2174/156800910793357934
Published on: 01 March, 2012

Histone Deacetylases: Anti-Angiogenic Targets in Cancer Therapy

Volume:10   Issue: 8
Pp: 898-913
D. Mottet and V. Castronovo
DOI: 10.2174/156800910793358014
Published on: 01 March, 2012

Endothelial Progenitor Cells: Hope Beyond Controversy

Volume:10   Issue: 8
Pp: 914-921
E. Pasquier and S. Dias
DOI: 10.2174/156800910793358041
Published on: 01 March, 2012

Inhibition of Membrane Complement Inhibitor Expression (CD46, CD55, CD59) by siRNA Sensitizes Tumor Cells to Complement Attack In Vitro

Volume:10   Issue: 8
Pp: 922-931
N. Geis, S. Zell, R. Rutz, W. Li, T. Giese, S. Mamidi, S. Schultz and M. Kirschfink
DOI: 10.2174/156800910793357952
Published on: 01 March, 2012

Tumor-Targeted Inhibition by a Novel Strategy - Mimoretrovirus Expressing siRNA Targeting the Pokemon Gene

Volume:10   Issue: 8
Pp: 932-941
Z. Tian, H. Wang, Z. Jia, J. Shi, J. Tang, L. Mao, H. Liu, Y. Deng, Y. He, Z. Ruan, J. Li, Y. Wu and B. Ni
DOI: 10.2174/156800910793357907
Published on: 01 March, 2012